Scholarlink

Introduction <p>This study aims to evaluate the short-term safety and efficacy of the Loong Crystal<sup>®</sup>PR lens, a novel posterior chamber phakic intraocular lens (PIOL) that utilizes advanced optical and material designs.</p> Methods <p>The single-center retrospective case series included 67 eyes of 34 patients with moderate and high myopia who underwent the PR implantation from February to July 2025. Corrected distant visual acuity (CDVA) and anterior chamber depth (ACD) were measured preoperatively. Uncorrected distant visual acuity (UDVA), refractive errors, higher-order aberrations (HOAs), intraocular pressure (IOP), and endothelial cell density (ECD) were measured preoperatively, at 1&#xa0;week, and at 1&#xa0;month postoperatively. The central and peripheral vault were measured on the operating day, at 1&#xa0;week, and at 1&#xa0;month after surgery.</p> Results <p>At 1&#xa0;month postoperatively, 95.5% of eyes achieved UDVA equal to or better than the preoperative CDVA. The efficacy index was 1.17 ± 0.19 at 1&#xa0;month postoperatively. Also, 94.0% of eyes achieved UDVA of 20/20 or better and 94.0% of eyes had residual spherical equivalent (SE) refraction within ± 1.00 D at 1&#xa0;month postoperatively, demonstrating excellent visual outcomes and refractive predictability. No significant difference in ECD was observed 1&#xa0;month postoperatively (3118.27 ± 180.95 cells/mm<sup>2</sup>) compared to the preoperative value (3081.12 ± 288.08 cells/mm<sup>2</sup>). Stable central and peripheral vaults remained at 376.27 ± 168.95&#xa0;μm and 485.72 ± 179.62&#xa0;μm, at postoperative 1&#xa0;month, respectively, compared to the surgery-day values of 373.51 ± 182.41&#xa0;μm and 486.24 ± 172.41&#xa0;μm, respectively. There were no significant differences of HOAs at postoperative 1&#xa0;month compared to the preoperative outcomes.</p> Conclusions <p>The Loong Crystal<sup>®</sup> PR lens demonstrates good, predictable efficacy and stability in correcting myopia, with a low risk of adverse events and complications at 1&#xa0;month postoperatively, indicating its short-term safety and efficacy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of Short-Term Safety and Efficacy of Myopia Correction with a Novel Posterior Chamber Phakic Intraocular Lens

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月24日

查看全文
  • Hui Zhang,
  • Yunfei Han,
  • Yu Yang,
  • Ling Ling,
  • Shu Xu,
  • Xuying Zhu,
  • Dikang Yang,
  • Xian Zhang,
  • Wentian Zhou

摘要

Introduction

This study aims to evaluate the short-term safety and efficacy of the Loong Crystal®PR lens, a novel posterior chamber phakic intraocular lens (PIOL) that utilizes advanced optical and material designs.

Methods

The single-center retrospective case series included 67 eyes of 34 patients with moderate and high myopia who underwent the PR implantation from February to July 2025. Corrected distant visual acuity (CDVA) and anterior chamber depth (ACD) were measured preoperatively. Uncorrected distant visual acuity (UDVA), refractive errors, higher-order aberrations (HOAs), intraocular pressure (IOP), and endothelial cell density (ECD) were measured preoperatively, at 1 week, and at 1 month postoperatively. The central and peripheral vault were measured on the operating day, at 1 week, and at 1 month after surgery.

Results

At 1 month postoperatively, 95.5% of eyes achieved UDVA equal to or better than the preoperative CDVA. The efficacy index was 1.17 ± 0.19 at 1 month postoperatively. Also, 94.0% of eyes achieved UDVA of 20/20 or better and 94.0% of eyes had residual spherical equivalent (SE) refraction within ± 1.00 D at 1 month postoperatively, demonstrating excellent visual outcomes and refractive predictability. No significant difference in ECD was observed 1 month postoperatively (3118.27 ± 180.95 cells/mm2) compared to the preoperative value (3081.12 ± 288.08 cells/mm2). Stable central and peripheral vaults remained at 376.27 ± 168.95 μm and 485.72 ± 179.62 μm, at postoperative 1 month, respectively, compared to the surgery-day values of 373.51 ± 182.41 μm and 486.24 ± 172.41 μm, respectively. There were no significant differences of HOAs at postoperative 1 month compared to the preoperative outcomes.

Conclusions

The Loong Crystal® PR lens demonstrates good, predictable efficacy and stability in correcting myopia, with a low risk of adverse events and complications at 1 month postoperatively, indicating its short-term safety and efficacy.